See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Liberation Day
Tariffs
Donald Trump
Trade War
Natural Disasters
Baseball
Senate
Republican Party
Social Media
Artificial Intelligence
Democratic Party
Tennis
Published • loading... • Updated

Palatin Drug Gets FDA’s Orphan Nod for Rare Type of Obesity

Summary by Inside Precision Medicine
Palatin Technologies announced the FDA has granted orphan drug designation to PL7737 for leptin receptor (LEPR) deficiency-related conditions, including obesity. PL7737 is an oral treatment that activates the melanocortin-4 receptor. Orphan drug designation aims to support products in development for rare diseases early in their development.  “This FDA orphan designation is a key step in developing Palatin’s MC4R receptor agonists for rare obesi…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

All
Left
Center
Right
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News

The Chronic Disease With No Clinical Classification

Is obesity among the most misunderstood, misclassified, and mistreated diseases? Over the past 30 years, researchers have not only identified a key hormone (leptin) that helps regulate appetite and body weight, but they’ve also determined the biologic underpinnings (eg, altered central nervous system pathways associated with energy balance) and discovered that obesity is often genetically […] The post The Chronic Disease With No Clinical Classif…

Read Full Article
Inside Precision MedicineInside Precision Medicine

Palatin Drug Gets FDA’s Orphan Nod for Rare Type of Obesity

Palatin Technologies announced the FDA has granted orphan drug designation to PL7737 for leptin receptor (LEPR) deficiency-related conditions, including obesity. PL7737 is an oral treatment that activates the melanocortin-4 receptor. Orphan drug designation aims to support products in development for rare diseases early in their development.  “This FDA orphan designation is a key step in developing Palatin’s MC4R receptor agonists for rare obesi…

Read Full Article
Pharmaceutical Business reviewPharmaceutical Business review

US FDA grants orphan drug status to Palatin's obesity treatment PL7737

This condition, caused by genetic mutations in the LEPR gene, leads to disrupted melanocortin-4 receptor (MC4R) signalling, resulting in extreme, constant hunger and severe early-onset obesity. PL7737, an The post US FDA grants orphan drug status to Palatin’s obesity treatment PL7737 appeared first on Pharmaceutical Business review.

Read Full Article
bariatricnews.netbariatricnews.net

Palatin's oral MC4R Agonist PL7737 receives FDA Orphan Drug Designation for obesity due to leptin receptor deficiency

Palatin Technologies has announced the FDA has granted "orphan drug" designation to PL7737, an oral treatment that activates the melanocortin-4 receptor (MC4R), for leptin receptor (LEPR) deficiency, including obesity caused by this condition.Obesity caused by LEPR deficiency is a rare genetic condition where mutations in the LEPR gene disrupt MC4R signalling. The Leptin-Melanocortin pathway in the hypothalamus plays a key role in regulating hun…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

bariatricnews.net broke the news in on Wednesday, March 26, 2025.
Sources are mostly out of (0)

Similar News Topics

Obesity

Obesity

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal